Skip to content
10-Q

Quarterly Report

Tobira Therapeutics, Inc.

0001564590-16-018581

← back to feed
Filed
May 9, 2016 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2016 · May 2, 2016 18.82M sh
Long Term Debt Q1 2016 · Mar 31, 2016 $13.97M
Long Term Debt Q1 2016 · Dec 31, 2015 $15.01M
Cash And Equivalents Q1 2016 · Mar 31, 2016 $52.34M
Cash And Equivalents Q1 2016 · Dec 31, 2015 $62.43M
Cash And Equivalents restated Q1 2016 · Mar 31, 2015 $13.18M
Cash And Equivalents restated Q1 2016 · Dec 31, 2014 $6.18M
Stockholders Equity Q1 2016 · Mar 31, 2016 $31.74M
Stockholders Equity Q1 2016 · Dec 31, 2015 $42.77M
Current Liabilities Q1 2016 · Mar 31, 2016 $9.94M
Current Liabilities Q1 2016 · Dec 31, 2015 $7.42M
Total Liabilities Q1 2016 · Mar 31, 2016 $24.09M
Total Liabilities Q1 2016 · Dec 31, 2015 $22.64M
Current Assets Q1 2016 · Mar 31, 2016 $53.5M
Current Assets Q1 2016 · Dec 31, 2015 $63.23M
Total Assets Q1 2016 · Mar 31, 2016 $55.83M
Total Assets Q1 2016 · Dec 31, 2015 $65.41M
Sga Expense Q1 2016 · Mar 31, 2016 $3.34M
Sga Expense restated Q1 2016 · Mar 31, 2015 $2.15M
Rd Expense Q1 2016 · Mar 31, 2016 $8.68M
Rd Expense restated Q1 2016 · Mar 31, 2015 $5.67M
Net Income Q1 2016 · Mar 31, 2016 −$12.22M
Net Income restated Q1 2016 · Mar 31, 2015 −$7.03M
Operating Income Q1 2016 · Mar 31, 2016 −$11.91M
Operating Income restated Q1 2016 · Mar 31, 2015 −$7.82M
Capex Q1 2016 · Mar 31, 2015 $22K